Citation Nr: 21011578 Decision Date: 03/02/21 Archive Date: 03/02/21 DOCKET NO. 15-04 161 DATE: March 2, 2021 ORDER Entitlement to an increased rating in excess of 10 percent prior to August 13, 2018, for chronic urticaria is denied. Entitlement to an increased rating in excess of 30 percent from August 13, 2018 forward for chronic urticaria is denied. FINDING OF FACT 1. Prior to August 13, 2018, the Veteran’s urticaria was manifested by flare-ups of the disability several times a year lasting one to two weeks, daily use of antihistamines, and the use of topical corticosteroids. 2. From August 13, 2018 forward, the Veteran’s urticaria was manifested by first line treatment consisting of antihistamines and second line treatment consisting of corticosteroids. CONCLUSION OF LAW 1. The criteria for an increased rating in excess of 10 percent prior to August 13, 2018 have not been met. 38 U.S.C. § 1155; 38 C.F.R. §§ 4.1, 4.2, 4.3, 4.7, 4.118, Diagnostic Code 7825. 2. The criteria for an increased rating in excess of 30 percent prior from August 13, 2018 forward for chronic urticaria have not been met. 38 U.S.C. § 1155; 38 C.F.R. §§ 4.1, 4.2, 4.3, 4.7, 4.118, Diagnostic Code 7825. REASONS AND BASES FOR FINDING AND CONCLUSION The Veteran served on active duty from August 1983 to September 2003. This matter is before the Board of Veterans’ Appeals (Board) on appeal from a rating decision issued in September 2011 by a Department of Veterans Affairs (VA) Regional Office (RO). The Board remanded the issues on appeal for additional development in July 2019, and the requested examination was conducted in September 2019. The current appeal was remanded again in August 2020, and the requested medical opinion was provided in November 2020. As such, the directives have been substantially complied with and the matter is again properly before the Board. D’Aries v. Peake, 22 Vet. App. 97, 105 (2008); Stegall v. West, 11 Vet. App. 268, 271 (1998). The Veteran testified at a hearing before the undersigned Veterans Law Judge (VLJ) in October 2018. A transcript of the hearing is of record. 1. Entitlement to an increased rating for chronic urticaria. Disability evaluations are determined by the application of the facts presented to VA’s Schedule for Rating Disabilities (Rating Schedule) at 38 C.F.R. Part 4. The percentage ratings contained in the Rating Schedule represent, as far as can be practicably determined, the average impairment in earning capacity resulting from diseases and injuries incurred or aggravated during military service and the residual conditions in civilian occupations. 38 U.S.C. § 1155; 38 C.F.R. §§ 3.321(a), 4.1. In evaluating the severity of a particular disability, it is essential to consider its history. 38 C.F.R. § 4.1; Peyton v. Derwinski, 1 Vet. App. 282 (1991). Where entitlement to compensation has already been established and an increase in the disability rating is at issue, the present level of disability is of primary importance. Francisco v. Brown, 7 Vet. App. 55, 58 (1994). Nevertheless, the Board acknowledges that a claimant may experience multiple distinct degrees of disability that might result in different levels of compensation from the time the increased rating claim was filed until a final decision is made. Hart v. Mansfield, 21 Vet. App. 505 (2007). The analysis in the following decision is therefore undertaken with consideration of the possibility that different ratings may be warranted for different time periods. If the evidence for and against a claim is in equipoise, the claim will be granted. 38 C.F.R. § 4.3. A claim will be denied only if the preponderance of the evidence is against the claim. 38 U.S.C. § 5107; 38 C.F.R. § 3.102; see Gilbert v. Derwinski, 1 Vet. App. 49, 56 (1990). Any reasonable doubt regarding the degree of disability should be resolved in favor of the claimant. 38 C.F.R. § 4.3. Where there is a question as to which of two evaluations shall be applied, the higher rating will be assigned if the disability picture more nearly approximates the criteria required for that evaluation. Otherwise, the lower rating will be assigned. 38 C.F.R. § 4.7. The Veteran’s chronic urticaria is rated under Diagnostic Code 7825. As an initial matter, the Board notes that the rating criteria contained in Diagnostic Code 7825 specifically, and in the rating schedule for disabilities of the skin generally, were amended effective August 13, 2018. 83 Fed. Reg. 32,592 (July 13, 2018) (eff. Aug. 13, 2018). In light of the amendment, the Board will consider both sets of criteria when evaluating whether increased ratings are possible under any other any alternative Diagnostic Codes, although if an increased rating is warranted under the revised criteria that award may not be made effective before the effective date of the change. See Kuzma v. Principi, 341 F.3d 1327 (Fed. Cir. 2003). Based on the foregoing, the Board will analyze the current claim under the criteria in effect prior to August 13, 2018, and will then consider whether an increased rating under the new criteria is possible from August 13, 2018, forward. Under the criteria in effect prior to the amendment, under Diagnostic Code 7825 a 10 percent rating was warranted for recurrent episodes of urticaria occurring at least four times during the past 12-month period, and that is responding to treatment with antihistamines or sympathomimetics. 38 C.F.R. § 4.118, Diagnostic Code 7825 (2017). A 30 percent rating was warranted for recurrent debilitating episodes of urticaria occurring at least four times during the past 12-month period and requiring intermittent systemic immunosuppressive therapy for control. Id. Finally, a 60 percent rating was warranted for recurrent debilitating episodes of urticaria occurring at least four times during the past 12-month period despite continuous immunosuppressive therapy. Id. During her October 2018 hearing before the undersigned, the Veteran reported that her skin disability affects approximately 60 percent of her total body area during outbreaks, affecting her thighs, back, arms and legs. The Veteran further reported that she experiences approximately six or seven outbreaks a year. The Veteran reported that she used to receive injections and had taken steroid treatments at some point, but primarily relied on topical creams and antihistamines for treatment. The Veteran is competent to report such lay-observable manifestations, and there is no evidence that her statements are not credible. Jandreau, 492 F.3d 1372. As such, her hearing testimony is entitled to significant probative weight. The Veteran also submitted lay statements from two other individuals in October 2018, both of whom attested to witnessing flare-ups of the Veteran’s disability in which the Veteran’s head, neck, body and legs were covered in red welts. These statements are competent as the appearance and location of a skin disability are facts that are observable by a third party. Id. There is no evidence that the statements are not credible, and therefore they are entitled to probative weight as to the severity of the Veteran’s disability. VA skin examinations were provided in April 2011, November 2014, September 2019 and November 2020. In April 2011, the examiner provided a diagnosis of urticaria. The Veteran reported recurrent flare-ups of the disability several times a year, each of which lasted approximately one to two weeks. The examiner noted that the Veteran used antihistamines on a daily basis and cortisone cream as needed, with both medications resulting in good responses. The examiner noted that less than five percent of exposed body area was affected and greater than five percent by less than 20 percent of total body area was affected. In November 2014, the examiner again provided a diagnosis of urticaria. The Veteran reported sporadic flare-ups of the disability, with the last occurring in March 2014. The Veteran reported that she used antihistamines and topical cream for treatment. The examiner further noted that she reported her last flare-up of the disability was mild and that she was not on preventative treatment. No scarring or systemic manifestations were present, and overall the examiner noted that the Veteran used topical medications for less than six weeks during the past 12 months. Finally, the examiner stated that there was no evidence of debilitating or non-debilitating episodes of urticaria in the past 12 months. During a September 2019 examination, the examiner also diagnosed the Veteran with urticaria. At the time of the examination the Veteran stated that the urticaria affects her lower back, arms, neck and lower extremities, and that it has last occurred approximately three weeks prior. Generally, the examiner noted that over the last 12-month period the Veteran had been treatment with antihistamines and a topical corticosteroid on a constant or near-constant basis, as well as doxepin as a pruritis reducer on a constant or near-constant basis. The examiner noted no other treatments for the skin disability. Concerning urticaria specifically, the examiner noted first line treatment of antihistamines and second line treatment of corticosteroids. The examiner also noted a third line treatment for pruritis reduction, which referred to the doxepin noted earlier in the report. An addendum opinion to the September 2019 examination was obtained in November 2020. The examiner stated that the third line treatment of doxepin was provided due to the ineffectiveness of the listed first- and second-line treatments. The examiner then stated that doxepin is a strong antihistamine that it effective at treating urticaria, explaining that doxepin acts as an antihistamine to block a hypersensitivity response of the immune system. The examiner then stated that there was no similarity or equivalence between the use of doxepin and the use of plasmapheresis, immunotherapy and immunosuppressants. The examiner stated that plasmapheresis is used to treat autoimmune disorders by removing antibodies that have been developed against self-tissue, and thus functions in a manner that is completely different from doxepin. Likewise, the examiner stated that immunotherapy and immunosuppressives are drugs used to suppress the body’s natural immune response in disease forms where the body is attacking itself. During a November 2020 examination, the Veteran reported no symptoms, with the examiner noting that the diagnosed urticaria was well-controlled with doxepin. The examiner noted that there was no treatment with any medication other than doxepin, nor was there any treatment or procedures other than systemic or topical treatment, including phototherapy, photochemotherapy, electron beam therapy, or intensive light therapy. The examiner stated that none of the Veteran’s total or exposed body area was affected, again stating that the urticaria was well-controlled with doxepin and that there was no evidence of hives anywhere on the Veteran’s body. No scarring or other symptoms were noted. There is no evidence that the above examiners were either not competent or credible. Further, each examiner’s assessment of the disability was based on both the Veteran’s reports of the severity of the disability, a review of the medical evidence and their own objective examinations. Further, the November 2020 opinion was supported by a well-reasoned rationale that discussed the differences in functioning between doxepin, plasmapheresis, immunotherapy and immunosuppressants. As such, the Board finds that each respective examination report and the November 2020 opinion are entitled to significant probative weight as to the severity of the Veteran’s disability during the period on appeal. Nieves-Rodriguez v. Peake, 22 Vet. App. 295 (2008). Private and VA treatment records reflect on-going treatment for urticaria, including the use of hydrocortisone cream and 50 mg of doxepin at bedtime for treatment. The records do not reflect the use of any immunosuppressive therapy. Based on the foregoing, increased ratings in excess of 10 percent prior to August 13, 2018 and in excess of 30 percent thereafter are not warranted in this case. Prior to August 13, 2018, there is no evidence of debilitating episodes occurring at least four times during any given 12-month period that also required intermittent systemic immunosuppressive therapy for control. None of the VA examiners indicated that the Veteran experienced debilitating episodes of urticaria during this period, nor do treatment records reflect flare-ups of the disability which are characterized as debilitating. Further, while the treatment records and examination reports note that the Veteran was prescribed doxepin and hydrocortisone cream, as discussed in the November 2020 opinion doxepin is not the same as or similar to immunosuppressive therapy, as it affects the body in a way that is completely different from immunosuppressants. Thus, even if debilitating episodes were present, the Veteran did not require immunosuppressive therapy of any frequency. Instead, the evidence reflects that the Veteran’s urticaria responded to the use of doxepin, an antihistamine, which more nearly approximates the level of severity contemplated by the assigned 10 percent rating. As such, the preponderance of the evidence is against a finding that an increased rating in excess of 10 percent prior to August 13, 2018 for urticaria under the pre-amendment criteria is warranted. 38 C.F.R. §§ 4.1, 4.3, 4.118, Diagnostic Code 7825 (2017). Likewise, an increased rating in excess of 30 percent from August 13, 2018 forward under the pre-amendment criteria is not warranted. As with the period prior to August 13, 2018, there is no evidence of immunosuppressive therapy, and as discussed in detail in the November 2020 opinion the use of doxepin, an antihistamine, is in no way the same as or similar to immunosuppressive therapy. Based on the foregoing, the preponderance of the evidence is against a finding that an increased rating in excess of 30 percent from August 13, 2018 forward under the pre-amendment criteria is warranted. 38 C.F.R. §§ 4.1, 4.3, 4.118, Diagnostic Code 7825 (2017). As discussed earlier, the rating criteria under Diagnostic Code 7825 were amended effective August 13, 2018. 83 Fed. Reg. 32,592 (July 13, 2018) (eff. Aug. 13, 2018). However, should an increased rating under the amended criteria be warranted in this case, such cannot be assigned prior to the effective date of the amendment. As such, the Board will now consider whether an increased rating is warranted under the post-amendment criteria, but only from August 13, 2018 forward. Kuzma, 341 F.3d 1327. Under the post-amendment criteria contained in Diagnostic Code 7825, chronic urticaria is defined as continuous urticaria at least twice per week, off treatment, for a period of six weeks or more. 38 C.F.R. § 4.118, Diagnostic Code 7825 (2019). A 10 percent rating is warranted for chronic urticaria that requires first line treatment (antihistamines) for control. Id. A 30 percent rating is warranted for chronic urticaria that requires second line treatment (e.g. corticosteroids, sympathomimetics, leukotriene inhibitors, neutrophil inhibitors, thyroid hormone) for control. Id. A 60 percent rating is warranted for chronic refractory urticaria that requires third line treatment for control (e.g. plasmapheresis, immunotherapy, immunosuppressives) due to ineffectiveness with first and second line treatments. Id. Based on the evidence as discussed above, a rating in excess of 30 percent from August 13, 2018 forward is not warranted. There is no evidence that the Veteran requires a third line treatment such as plasmapheresis, immunotherapy or immunosuppressives. The Board notes that the September 2019 examiner noted doxepin as a third line treatment, and the November 2020 opinion stated that it was listed due to the ineffectiveness of the first and second line treatments. However, the November 2020 opinion continued on to explain that doxepin, an antihistamine, is not the same or similar to the either plasmapheresis, immunotherapy or immunosuppressives, as the later three treatments affect the body and generally function in extremely different ways. While the treatments listed at the 60 percent rating under the post-amendment criteria are not an exhaustive list, any third line treatment must still be the same or similar to the listed treatments. MERRIAM-WEBSTER’S COLLEGIATE DICTIONARY 398 (11 ed. 2003) (defining e.g. as “for example”); see Mauerhan v. Principi, 16 Vet. App. 436, 442 (2002) (noting that the use of “for example” does not represent and exhaustive list of symptoms); see also Vasquez-Claudio v. Shinseki, 713 F.3d 112, 116–17 (Fed. Cir. 2013) (stating that unlisted symptoms must still be of the same or similar severity to those listed at a higher rating in order to warrant the higher rating). As the evidence of record reflects that doxepin, an antihistamine, is not the same or similar to treatment with plasmapheresis, immunotherapy or immunosuppressives, the preponderance of the evidence is against a finding that an increased rating in excess of 30 percent from August 13, 2108 forward under the post-amendment criteria is warranted in this case. 38 C.F.R. §§ 4.3, 4.7, 4.118, Diagnostic Code 7825 (2019). While the Veteran has reported extensive body coverage during flare-ups of the disability and the use of oral and topical medication, the post-August 2018 amendment criteria specifically states that the new general formula for rating skin disabilities does not apply to Diagnostic Code 7825. 38 C.F.R. § 4.118, General Rating Formula for the Skin. As such, higher ratings based on the criteria contained in the General Formula cannot be assigned for the Veteran’s urticaria. Further, the Veteran has only been diagnosed with urticaria, which is specifically covered by Diagnostic Code 7825. As such, it would be inappropriate to rate this disability by analogy to any other Diagnostic Codes. Copeland v. McDonald, 27 Vet. App. 333, 336–37 (2015) (“the Court reiterates that when a condition is specifically listed in the Schedule, it may not be rated by analogy”). Thus, consideration of any alternative Diagnostic Codes is not warranted in this case. The Board notes that the Veteran has reported symptoms not directly contemplated by the rating criteria governing urticaria, including itching and body area coverage. Thun v. Peake, 22 Vet. App. 111, 116 (2008). However, the medical evidence does not reflect that the Veteran’s urticaria result in frequent hospitalizations, nor is there evidence that the disability results in marked interference with the Veteran’s employment. While the Veteran has reported having to wear long-sleeved garments at work due to her urticaria, there is no evidence that she misses a marked or distinct amount of work. See MERRIAM-WEBSTER’S COLLEGIATE DICTIONARY 364, 760 (11 ed. 2003). As such, referral for extraschedular consideration is not warranted in this case. Thun, 22 Vet. App. at 116; Chudy v. O’Rourke, 30 Vet. App. 34 (2018). All potentially applicable Diagnostic Codes have been considered. See Schafrath v. Derwinski, 1 Vet. App. 589, 593 (1991). The preponderance of the evidence is against an increased rating in excess of 10 percent prior to August 13, 2018, and in excess of 30 percent thereafter for the Veteran’s service-connected urticaria. As such, the benefit-of-the-doubt doctrine is inapplicable. 38 C.F.R. § 4.3. For these reasons, the claim is denied. LESLEY A. REIN Veterans Law Judge Board of Veterans’ Appeals Attorney for the Board C. Wendell, Counsel The Board’s decision in this case is binding only with respect to the instant matter decided. This decision is not precedential and does not establish VA policies or interpretations of general applicability. 38 C.F.R. § 20.1303.